BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oxford BioMedica PLC (OXB.L) to Present at Conference


8/29/2012 9:49:54 AM

OXFORD, UNITED KINGDOM--(Marketwire - August 29, 2012) -


Oxford BioMedica to Present at the 2012 Rodman & Renshaw Annual Global
Investment Conference



-- 14th Annual Healthcare Conference --



Oxford, UK - 29 August 2012: Oxford BioMedica plc ("Oxford BioMedica"
or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical
company, today announces that John Dawson, Chief Executive Officer of
Oxford BioMedica, will present at the Rodman & Renshaw Annual Global
Investment Conference to be held on September 9-11, 2012 at The Waldorf
Astoria, NY (USA).



The presentation is scheduled for Monday, 10 September 2012 at 16:30
Eastern Time. A copy of the slide presentation will be made available
on the "Investors/Corporate presentations" section of the Company's
website at www.oxfordbiomedica.co.uk.



-Ends-



For further information, please contact:

Oxford BioMedica plc:                              Tel: +44 (0)1865 783
                                                   000
Lara Mott, Head of Corporate Communications

Media Enquiries:                                   Tel: +44 (0)20 7920
                                                   2360
Mary Clark/Sarah Macleod/Claire Dickinson
M:Communications




Notes to editors



1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company
developing innovative gene-based medicines and therapeutic vaccines
that aim to improve the lives of patients with high unmet medical
needs. The Company's technology platform includes a highly efficient
LentiVector® gene delivery system, which has specific advantages for
targeting diseases of the central nervous system and the eye; and a
unique tumour antigen (5T4), which is an ideal target for anti-cancer
therapy. Through in-house and collaborative research, Oxford BioMedica
has a broad pipeline with current partners and licensees including
Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is available
at www.oxfordbiomedica.co.uk.

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES